Evidence map›Paper›PMID 40866264›Full record

ArticleInternal medicine (Tokyo, Japan)2026

Fulminant Type 1 Diabetes Induced by Immune Checkpoint Inhibitors in a Patient with Autoimmune Predisposition.

Miyu Tomiki, Keiichiro Matoba, Kensuke Sekiguchi, Shunichi Jinnai, Rimei Nishimura

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Miyu TomikiDivision of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, The Jikei University School of Medicine, Japan.
Keiichiro MatobaDivision of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, The Jikei University School of Medicine, Japan.
Kensuke SekiguchiDivision of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, The Jikei University School of Medicine, Japan.
Shunichi JinnaiDepartment of Dermatologic Oncology, National Cancer Center Hospital East, Japan.
Rimei NishimuraDivision of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, The Jikei University School of Medicine, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report a case of fulminant type 1 diabetes in a 73-year-old woman who was treated with nivolumab and ipilimumab for plantar malignant melanoma. Despite carrying the protective HLA-DRB1*15:01-DQB1*06:02 haplotype, she developed marked hyperglycemia (596 mg/dL), ketoacidosis, anti-glutamic acid decarboxylase (GAD) antibody positivity, HbA1c 6.6%, and low urinary C-peptide (1.0 μg/day). The detection of anti-GAD antibodies suggests an underlying autoimmune predisposition, which is likely aggravated by immune checkpoint inhibitors. Her history of Graves' disease and familial autoimmunity further supports this predisposition. This case highlights the importance of monitoring endocrine immune-related adverse events in patients with autoimmune backgrounds.

Indexed as

Diabetes Mellitus, Type 1Immune Checkpoint InhibitorsAgedAutoantibodiesFemaleGenetic Predisposition to DiseaseHumansIpilimumabMelanomaNivolumabAutoantibodiesImmune Checkpoint InhibitorsIpilimumabNivolumabanti-GAD antibodyfulminant type 1 diabetesGraves' diseaseimmune checkpoint inhibitors

Identifiers

PMID40866264
PMCPMC13070604

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.